ArticleHereditas2025
LncRNA LEF1-AS1 exerts a carcinogenic effect in breast cancer by accelerating proliferation, metastasis, and epithelial-mesenchymal transition.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer (BRCA) directly poses a threat to human life safety. This study aims to explore the role of lncRNA LEF1-AS1 in BRCA.
methodsFirstly, the levels of LEF1-AS1 in tumor tissues and BRCA cells were detected by qRT-PCR. Furthermore, LEF1-AS1 was inhibited through cell transfection. Subsequently, the proliferation, apoptosis and migration abilities of the cells were detected using the CCK-8 assay, flow cytometry and Transwell assay. Meanwhile, the mRNA levels of epithelial-mesenchymal transition (EMT) markers were also measured. The targeting binding relationships between LEF1-AS1 and miR-328-5p, as well as between miR-328-5p and KLF16, were verified by dual luciferase reporter assays and RNA pull-down assays. Furthermore, the effects of co-regulating LEF1-AS1 and miR-328-5p and down-regulating KLF16 on tumor cells were further investigated.
resultsIn tumor tissues and BRCA cell lines, LEF1-AS1 is highly expressed. Downregulation of LEF1-AS1 inhibits the malignant proliferation of BRCA cells and reduces their migration ability. Moreover, the process of EMT is significantly inhibited. miR-328-5p is the downstream target of LEF1-AS1. Simultaneously inhibiting miR-328-5p and LEF1-AS1 weakens the anti-cancer effect resulting from LEF1-AS1 silencing. LEF1-AS1 mainly participates in tumor progression by acting as a sponge molecule for miR-328-5p. Inhibiting LEF1-AS1 leads to the downregulation of KLF16, while the inhibition of miR-328-5p leads to the upregulation of KLF16. Moreover, the downregulation of KLF16 will result in weakened proliferation and migration abilities of BRCA cells.
conclusionsLEF1-AS1 increases the level of KLF16 by sponging miR-328-5p, thereby promoting the proliferation, metastasis and EMT of BRCA cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.